Trabectedin for recurrent grade 2 or 3 meningiomas

Dr. Iyad Alnahhas interviews Dr. Matthias Preusser about the recent manuscript entitled: "Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG)", published online in Neuro-Oncology in October 2021.

Om Podcasten

Neuro-Oncology: The Podcast will keep you up to date about the latest advances in the field as we present conversations with the authors of selected papers from Neuro-Oncology and its sister journals, Neuro-Oncology Practice and Neuro-Oncology Advances.